Status:
COMPLETED
Improving Neuroprotective Strategy for Ischemic Stroke After Thrombectomy Followed by DELP (INSIST-DELP)
Lead Sponsor:
General Hospital of Shenyang Military Region
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) has been found to improve neurological function and life ability of AIS patients and approved for the treatment of AIS by China Food and Dr...
Eligibility Criteria
Inclusion
- Age ≥18 years;
- acute anterior circulatory cerebral infarction with large vessel occlusion;
- NIHSS≥6 before endovascular treatment;
- good recanalization (TICI 2b-3);
- time from onset to groin puncture is less than 8 hours;
- time from recanalization to DELP is less than 2 hours;
- Premorbid mRS 0 or 1;
- Signed informed consent.
Exclusion
- poor recanalization (TICI 1-2a);
- Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ \<100000/mm3;
- Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;
- Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);
- Previous allergy to heparin or calcium;
- hypoproteinemia;
- Unsuitable for this clinical studies assessed by researcher.
Key Trial Info
Start Date :
August 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 8 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04708730
Start Date
August 15 2021
End Date
February 8 2024
Last Update
March 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology, General Hospital of Northern Theater Command
Shenyang, China, 110016